Imagine living with a condition where your own body turns against you, creating painful tunnels that burrow through your tissues, sometimes even connecting organs or breaking through your skin. This is the harsh reality for about 30% of people with Crohn's disease, a chronic condition affecting roughly 1 in 650 individuals. But here's where it gets controversial: while we've known about these debilitating fistulas for years, their exact cause and why they're so stubbornly resistant to treatment has remained a mystery—until now. Scientists at the University of Oxford have finally cracked the code, uncovering the rogue cells behind this devastating complication.
Crohn's disease isn't just about occasional stomachaches; it's a relentless battle where parts of the gut become swollen, inflamed, and ulcerated. When these ulcers or inflamed areas fail to heal properly, fistulas can form, creating tunnel-like passages that wreak havoc on the body. Despite their impact, the mechanisms driving their formation and persistence have been unclear—until this groundbreaking study, published in Nature (https://www.nature.com/articles/s41586-025-09744-y).
Using cutting-edge single-cell and spatial analysis techniques, researchers at the MRC Weatherall Institute of Molecular Medicine (https://www.imm.ox.ac.uk/) examined thousands of individual cells from Crohn's fistulas, comparing them to healthy gut tissue. What they found was astonishing: fistulas are lined with concentric rings of fibroblasts—cells typically responsible for maintaining tissue structure—that have gone rogue. These fibroblasts have been reprogrammed to behave like cells involved in early fetal gut development, a process that should only occur before birth. This out-of-context activity is a double-edged sword: fibroblasts near the surface destroy surrounding tissue, promoting tunneling, while deeper fibroblasts produce stiff, fibrotic material that stabilizes the tunnels, ensuring their persistence.
And this is the part most people miss: traces of these abnormal fibroblasts were also found in small numbers at the bases of ulcers in Crohn's patients who hadn't yet developed fistulas. This suggests that early intervention could potentially prevent fistulas from forming altogether. But here’s the question: could we be on the brink of a new era in Crohn's treatment, or are we still years away from translating these findings into effective therapies? Let us know what you think in the comments.
Dr. Agne Antanaviciute (https://www.imm.ox.ac.uk/people/agne-antanaviciute), one of the senior authors, explains, 'These fibroblasts have essentially reactivated developmental programs that should only be active before birth. This reawakening makes them highly destructive, eroding tissue at the surface while laying down fibrotic scar tissue deeper in the tract, helping the tunnels form and persist.'
Professor Alison Simmons (https://www.rdm.ox.ac.uk/people/alison-simmons), Director of the MRC Translational Immune Discovery Unit (https://www.imm.ox.ac.uk/research/units-and-centres/mrc-translational-immune-discovery-unit), adds, 'Current Crohn's medications focus on suppressing inflammation but do little to promote tissue repair. By identifying the cell types and pathways driving fistula formation, we now have the vital information needed to design and test preventive measures and novel wound-healing approaches.'
The Oxford team's work has produced the largest dataset of its kind, integrating single-cell, spatial, and molecular imaging data across diverse patient samples. All data have been made publicly available to accelerate global research into Crohn's complications. This isn't just a scientific breakthrough—it's a beacon of hope for millions suffering from this debilitating condition.
Clinical researcher Colleen McGregor (https://www.rdm.ox.ac.uk/people/colleen-mcgregor), co-first author of the study, shares her excitement: 'As a clinician who sees firsthand the burden of this complication, I'm thrilled to have helped define key aspects of fistula biology—an area where data have long been limited. This work highlights the power of interdisciplinary collaboration between clinical medicine and science, the cornerstone of high-quality IBD care.'
The study, Spatial Fibroblast Niches Defining Crohn's Fistulae (https://www.nature.com/articles/s41586-025-09744-y), was generously supported by the UKRI Medical Research Council (MRC) (https://www.ukri.org/councils/mrc/), the Leona M. and Harry B. Helmsley Charitable Trust (https://helmsleytrust.org/), the National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre (https://oxfordbrc.nihr.ac.uk/), and the Wellcome Trust (https://wellcome.org/).
This research opens a new frontier in drug discovery, aiming to restore healthy cell communication and wound healing within the gut—a critical step toward therapies that could prevent or reverse one of Crohn's most devastating complications. But the question remains: will these findings lead to a cure, or are we still scratching the surface? Share your thoughts below!
